The American Society of Clinical Oncology (ASCO)’s annual meeting kicks off Friday in Chicago, with more than 5,000 abstracts highlighting investigational therapies for various malignancies. Analysts have expressed particular excitement for a new bispecific antibody, ADCs and a BCMA-targeted CAR-T cell therapy.
Stay tuned to BioSpace as we keep you updated on all of the biggest data and news from the conference.
Updated: June 1, 3:30 PM EST/2:30 PM CST
Takeda and Pfizer’s Hodgkin Lymphoma Combo Improves Survival
On Saturday, Pfizer and Takeda posted positive results for a combination of the antibody-drug conjugate Adcetris in Hodgkin’s lymphoma.
According to Pfizer and Takeda, which has the commercialization rights to Adcetris outside of the U.S. and Canada, the Phase III HD21 study evaluated the ADC in combination with several other cancer treatments such as etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (BrECADD). The combination was pitted against the standard of care, a cocktail of seven cancer drugs, in newly diagnosed Stage IIb/III/IV classical Hodgkin’s lymphoma patients. The three-year analysis found that the experimental combination had met the co-primary endpoints, displaying improved safety and “non-inferior” progression-free survival (PFS).
After 48 months, the ADC combination has shown a “superior efficacy” to the standard of care, netting 94.3% in PFS versus 90.9% with a p-value of p<0.035. Treatment-related morbidity was also lower than the standard of care at 42% versus 59% (p<0.001). The study also found that the Adcetris combo had an improved risk-to-benefit profile compared to the current standard.
“We initiated the HD21 trial with the hope of improving outcomes currently being achieved by a standard of care, as many patients with newly diagnosed disease often experience a high treatment burden,” Peter Borchmann of the University Hospital of Cologne, Germany, and trial chairman of the HD21 study said in a statement. “The presented analysis, in which the ADCETRIS regimen demonstrates superior progression-free survival, as well as a tolerable safety profile, reveals the meaningful potential this ADCETRIS + ECADD regimen has to offer these patients.”
Pfizer has also presented encouraging results for its ALK- inhibitor Lorbrena at ASCO.
BMS’s Krazati Reaches Primary Endpoint in NSCLC
Bristol Myers Squibb announced on Saturday at the American Society of Clinical Oncology (ASCO) annual meeting that the small-molecule KRASG12C inhibitor Krazati had reached its primary endpoint in a Phase III trial in non-small cell lung cancer (NSCLC).
According to BMS, the Phase III Krystal-12 trial pitted Krazati against chemotherapy in patients with locally advanced or metastatic KRASG12C-mutated NSCLC who have already received docetaxel. The results showed that the treatment induced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at a median follow-up of 9.4 months. The median PFS was 5.5 months for Krazati, compared to 3.8 in the chemotherapy arm. The overall response rate (ORR) was also higher in Krazati versus docetaxel, with a p-value of p<0.0001. The median duration of response was 8.31 months in Krazati patients versus 5.36 months in the chemo arm.
Krazati also had an intracranial response among patients with central nervous system metastases and displayed a response rate that was more than double that of docetaxel. BMS said that the study is ongoing and will assess the secondary endpoint of overall survival.
“These confirmatory results further support KRAZATI as an efficacious, targeted treatment option for these patients,” Abderrahim Oukessou, vice president and global program lead for KRAZATI at BMS, said in a statement. “We look forward to further sharing these results while also continuing to evaluate KRAZATI in other advanced KRASG12C-mutated solid tumors.”
Krazati came into BMS’s possession late last year when it acquired Mirati Therapeutics for $4.8 billion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.